A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group.

@article{Shiraki1998APS,
  title={A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. The Alendronate Research Group.},
  author={Makoto Shiraki and Kazuhiro Kushida and Masao Fukunaga and Hideaki Kishimoto and Kiyoshi Kaneda and Hiroshi Minaguchi and Tetsuo Inoue and Akio Tomita and Yukihiro Nagata and Michi Nakashima and Hajime Orimo},
  journal={Endocrine journal},
  year={1998},
  volume={45 2},
  pages={191-201}
}
Alendronate (4-amino-1-hydroxybutylidene-1,1-bisphosphonate) is a potent inhibitor of bone resorption. The efficacy and safety of 36 weeks of treatment with alendronate were evaluated in Japanese women with osteoporosis, osteoporotic osteopenia or artificial menopause. The bone mineral density (BMD) of the lumbar vertebrae, markers of bone and calcium metabolism and clinical symptoms were monitored. A total of 113 randomly selected patients with osteoporosis or osteopenia were enrolled in the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 28 extracted citations

Similar Papers

Loading similar papers…